Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023

SELL
$25.44 - $59.78 $2.9 Million - $6.82 Million
-114,088 Reduced 45.14%
138,656 $3.77 Million
Q3 2022

Feb 14, 2023

SELL
$43.66 - $61.0 $224,499 - $313,662
-5,142 Reduced 1.99%
252,744 $13.6 Million
Q3 2022

Nov 14, 2022

SELL
$43.66 - $61.0 $224,499 - $313,662
-5,142 Reduced 1.99%
252,744 $13.6 Million
Q2 2022

Feb 14, 2023

SELL
$28.82 - $77.35 $114,386 - $307,002
-3,969 Reduced 1.52%
257,886 $10.4 Million
Q2 2022

Aug 15, 2022

SELL
$28.82 - $77.35 $114,386 - $307,002
-3,969 Reduced 1.52%
257,886 $10.4 Million
Q1 2022

Feb 14, 2023

BUY
$48.25 - $100.49 $439,605 - $915,564
9,111 Added 3.6%
261,855 $17.3 Million
Q1 2022

May 13, 2022

SELL
$48.25 - $100.49 $403,659 - $840,699
-8,366 Reduced 3.1%
261,855 $17.3 Million
Q4 2021

Feb 14, 2022

BUY
$88.71 - $120.43 $622,832 - $845,539
7,021 Added 2.67%
270,221 $27 Million
Q3 2021

Nov 15, 2021

BUY
$98.77 - $132.17 $12.8 Million - $17.1 Million
129,404 Added 96.72%
263,200 $32.9 Million
Q2 2021

Aug 13, 2021

BUY
$109.77 - $165.68 $3.77 Million - $5.69 Million
34,335 Added 34.52%
133,796 $16.6 Million
Q1 2021

May 14, 2021

BUY
$127.04 - $179.1 $234,261 - $330,260
1,844 Added 1.89%
99,461 $15.2 Million
Q4 2020

Feb 12, 2021

BUY
$99.96 - $135.93 $393,442 - $535,020
3,936 Added 4.2%
97,617 $12.6 Million
Q3 2020

Nov 13, 2020

SELL
$80.32 - $111.8 $465,775 - $648,328
-5,799 Reduced 5.83%
93,681 $10.5 Million
Q2 2020

Aug 14, 2020

BUY
$60.49 - $97.5 $901,542 - $1.45 Million
14,904 Added 17.62%
99,480 $8.07 Million
Q1 2020

May 15, 2020

BUY
$59.04 - $88.81 $4.99 Million - $7.51 Million
84,576 New
84,576 $5.89 Million

Others Institutions Holding GH

About Guardant Health, Inc.


  • Ticker GH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 102,220,000
  • Market Cap $4.41B
  • Description
  • Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a cl...
More about GH
Track This Portfolio

Track Axa S.A. Portfolio

Follow Axa S.A. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Axa S.A., based on Form 13F filings with the SEC.

News

Stay updated on Axa S.A. with notifications on news.